Search Results
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer
MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancer
MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer
monarchE: adjuvant abemaciclib in HR+ breast cancer
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
monarchE: patient-reported outcomes
Erika Hamilton, MD, considers the significance of the monarchE study & the use of abemaciclib
Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure